Ancre
  • Public-private partnership

    Against the background of increases in the number of cardiac patients and significant research developments, the Pasteur Clinic and the Toulouse University Hospital decided to pool their clinical research expertise in cardiology, beginning with interventional cardiology.

     

    This project gave birth to the creation of the Toulouse Clinical Research Centre for Cardiology, Toulouse CR2C.

     

    Toulouse boasts two organisations, one private, the other public, which are recognised in France and across Europe for their expertise in cardiology. In fact, the Pasteur Clinic and the Toulouse University Hospital rank first in France in the field of interventional cardiology, with 5000 coronary angioplasties performed and 300 percutaneous aortic valves fitted annually.

      

    Contacts

  • Role and objectives

    By bringing together teams of excellence, such cooperation will serve to build upon and harmonise the clinical research activities of both institutions, particularly through information exchange and joint decision-making on clinical trials involving interventional cardiology.

     

    The Toulouse CR2C will give manufacturers of medical devices and medicinal products easier access to patients recruited by the two teams. This is sure to fuel the drive towards making the proposed inclusions within the time frame and will see a commitment by both institutions to provide speedy results on feasibility.

     

    By creating the Toulouse Clinical Research Centre for Cardiology, the Pasteur Clinic and the Toulouse University Hospital are aiming to become one of the first European referral centres for clinical research in interventional cardiology.

      

  • Patient-focused expertise

    This centre will pave the way for setting up a research platform to enable new treatment and diagnostic strategies to be developed for eventual use on heart disease patients.

     

    The Toulouse CR2C will enhance the appeal of Toulouse as a hub for cardiology research and will offer patients additional options for access to innovative treatment via research protocols.